GILEAD SCIENCES, INC.
StreetZero Signal 60
About GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
LATEST FUNDINGRule 144
$469K
Announced 2026-10-15
IN THE NEWS
EMPLOYEES—
FOUNDED—
HQFoster City, California, United States
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalPublic EquityNASDAQ
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Allocated $3 million in grant funding to eight organizations via its Zeroing In initiative targeting HIV disparities in rural U.S. communities.
- Debuted on NASDAQ in January 1992 with an IPO that raised $86.25 million.
- Maintains operations in more than 35 countries worldwide.
Ask StreetZero about GILEAD SCIENCES, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account